P252 Proposed plan for oxygen therapy as an adjuvant to antibiotics in cystic fibrosis

Abstract

There is a clear need for new antibiotics to improve the efficacy of long-term antimicrobial therapy in pwCF. Cefiderocol is currently licensed for the treatment of infections due to Gram-negative organisms with limited treatment options. The aim of this study was to determine the susceptibility of a broad range of CF Gram-negative pathogens to cefiderocol and relevant comparator antibiotics.